← Back to searchRecruitingRecruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
NCT06295965 · University of Washington
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
About this study
OUTLINE: This is an observational study.
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
Eligibility criteria
Inclusion Criteria:
* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
* Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
OR
* Subjects who have or have had a solid tumor diagnosis and any of the following:
* At least 4 months of exposure to a PARP inhibitor
* Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
Exclusion Criteria:
* Individuals with a life expectancy of less than 6 months
Study design
Enrollment target: 2000 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2024-01-02
Estimated completion: 2031-12-31
Last updated: 2026-04-17
Interventions
Other: Non-Interventional Study
Primary outcomes
- • Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients (Through study completion, up to 5 years)
- • Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors (Through study completion, up to 5 years)
- • Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN (Through study completion, up to 5 years)
Sponsor
University of Washington · other
With: National Cancer Institute (NCI)
Contacts & investigators
ContactSwisher Lab Research Coordinators · contact · swisherlabrc@uw.edu · 206-616-8927
InvestigatorElizabeth Swisher · principal_investigator, Fred Hutch/University of Washington Cancer Consortium
All locations (1)
Fred Hutch/University of Washington Cancer ConsortiumRecruiting
Seattle, Washington, United States